ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells $14,205.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 250 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $56.82, for a total transaction of $14,205.00. Following the transaction, the vice president now owns 56,738 shares of the company’s stock, valued at $3,223,853.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Meredith Cook also recently made the following trade(s):

• On Tuesday, August 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $59.62, for a total value of $14,905.00.
• On Friday, July 12th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $64.91, for a total value of $16,227.50.

ANI Pharmaceuticals Stock Up 1.6 %

Shares of NASDAQ ANIP opened at $61.05 on Thursday. The company has a 50 day simple moving average of $61.22 and a 200 day simple moving average of $63.78. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. ANI Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $70.81. The firm has a market cap of $1.28 billion, a PE ratio of 38.16 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The firm had revenue of $138.00 million during the quarter, compared to the consensus estimate of $129.09 million. During the same quarter last year, the firm earned $1.06 earnings per share. The company’s revenue for the quarter was up 18.5% on a year-over-year basis. On average, research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.5 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Innealta Capital LLC acquired a new stake in shares of ANI Pharmaceuticals in the second quarter valued at about $65,000. Ridgewood Investments LLC acquired a new stake in ANI Pharmaceuticals during the 2nd quarter valued at approximately $85,000. SG Americas Securities LLC bought a new position in ANI Pharmaceuticals during the 1st quarter worth approximately $106,000. ADAR1 Capital Management LLC acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter worth approximately $132,000. Finally, Clear Street Markets LLC bought a new stake in shares of ANI Pharmaceuticals in the 4th quarter valued at $140,000. 76.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ANIP has been the subject of several research analyst reports. Raymond James boosted their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday. HC Wainwright reissued a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Tuesday. Truist Financial restated a “hold” rating and issued a $60.00 target price (down previously from $80.00) on shares of ANI Pharmaceuticals in a research report on Wednesday, September 11th. Finally, StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $78.80.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.